(Q38234350)

PubMed publication ID

25065704

31 August 2017

title

Summary of the 8th Annual Bladder Cancer Think Tank: Collaborating to move research forward (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6776416&resulttype=core&format=json

12 May 2020

1 reference

1 reference

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6776416&resulttype=core&format=json

12 May 2020

Jonathan E Rosenberg

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6776416&resulttype=core&format=json

12 May 2020

author name string

Andrea B Apolo

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6776416&resulttype=core&format=json

12 May 2020

Vanessa Hoffman

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6776416&resulttype=core&format=json

12 May 2020

Matthew G Kaag

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6776416&resulttype=core&format=json

12 May 2020

Cheryl T Lee

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6776416&resulttype=core&format=json

12 May 2020

Margaret Knowles

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6776416&resulttype=core&format=json

12 May 2020

Dan Theodorescu

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6776416&resulttype=core&format=json

12 May 2020

Bogdan A Czerniak

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6776416&resulttype=core&format=json

12 May 2020

Jason A Efstathiou

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6776416&resulttype=core&format=json

12 May 2020

Matthew L Albert

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6776416&resulttype=core&format=json

12 May 2020

Srikala S Sridhar

12

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6776416&resulttype=core&format=json

12 May 2020

Vitaly Margulis

13

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6776416&resulttype=core&format=json

12 May 2020

Surena F Matin

14

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6776416&resulttype=core&format=json

12 May 2020

Matthew D Galsky

15

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6776416&resulttype=core&format=json

12 May 2020

Donna Hansel

16

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6776416&resulttype=core&format=json

12 May 2020

Ashish M Kamat

17

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6776416&resulttype=core&format=json

12 May 2020

Thomas W Flaig

18

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6776416&resulttype=core&format=json

12 May 2020

Angela B Smith

19

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6776416&resulttype=core&format=json

12 May 2020

Edward Messing

20

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6776416&resulttype=core&format=json

12 May 2020

Diane Zipursky Quale

21

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6776416&resulttype=core&format=json

12 May 2020

Yair Lotan

22

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6776416&resulttype=core&format=json

12 May 2020

publication date

25 July 2014

1 reference

PubMed publication ID

31 August 2017

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6776416&resulttype=core&format=json

12 May 2020

volume

33

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6776416&resulttype=core&format=json

12 May 2020

issue

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6776416&resulttype=core&format=json

12 May 2020

page(s)

53-64

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6776416&resulttype=core&format=json

12 May 2020

cites work

Cancer statistics, 2013

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2014.06.013

Occupational cancer in Britain. Urinary tract cancers: bladder and kidney

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2014.06.013

Epidemiology and risk factors of urothelial bladder cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2014.06.013

Association between smoking and risk of bladder cancer among men and women

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2014.06.013

Unexplained excess risk of bladder cancer in men.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2014.06.013

Who should be included in a clinical trial of screening for bladder cancer?: a decision analysis of data from the Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2014.06.013

Predicting risk of bladder cancer using clinical and demographic information from prostate, lung, colorectal, and ovarian cancer screening trial participants

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2014.06.013

Promotion of bladder cancer development and progression by androgen receptor signals.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2014.06.013

Androgenic dependence of exophytic tumor growth in a transgenic mouse model of bladder cancer: a role for thrombospondin-1.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2014.06.013

Decreased bladder cancer growth in parous mice.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2014.06.013

Decreased tumorigenesis and mortality from bladder cancer in mice lacking urothelial androgen receptor.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2014.06.013

Androgen regulation of CYP4B1 responsible for mutagenic activation of bladder carcinogens in the rat bladder: detection of CYP4B1 mRNA by competitive reverse transcription-polymerase chain reaction

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2014.06.013

CD24 offers a therapeutic target for control of bladder cancer metastasis based on a requirement for lung colonization

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2014.06.013

CD24 expression is important in male urothelial tumorigenesis and metastasis in mice and is androgen regulated

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2014.06.013

Androgen receptor promotes the migration and invasion of upper urinary tract urothelial carcinoma cells through the upregulation of MMP-9 and COX-2.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2014.06.013

Long-term results of standard procedures in urology: the ileal neobladder.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2014.06.013

Optimal use and outcomes of orthotopic neobladder reconstruction in men and women

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2014.06.013

Nerve-sparing radical cystectomy and orthotopic bladder replacement in female patients.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2014.06.013

Preservation of the internal genital organs during radical cystectomy in selected women with bladder cancer: a report on 15 cases with long term follow-up.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2014.06.013

Uterus-, fallopian tube-, ovary-, and vagina-sparing cystectomy followed by U-shaped ileal neobladder construction for female bladder cancer patients: oncological and functional outcomes.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2014.06.013

Defecation disturbances after cystectomy for urinary bladder cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2014.06.013

Survey says patients expect little physician help on sex.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2014.06.013

Role of FGFR3 in urothelial cell carcinoma: biomarker and potential therapeutic target

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2014.06.013

Fibroblast growth factor receptor-3 in urothelial tumorigenesis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2014.06.013

Parallel RNA interference screens identify EGFR activation as an escape mechanism in FGFR3-mutant cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2014.06.013

Fibroblast growth factor receptor 3 is a rational therapeutic target in bladder cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2014.06.013

Understanding the development of human bladder cancer by using a whole-organ genomic mapping strategy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2014.06.013

Genetic modeling of human urinary bladder carcinogenesis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2014.06.013

Forerunner genes contiguous to RB1 contribute to the development of in situ neoplasia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2014.06.013

7 January 2021

Focus on bladder cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2014.06.013

Molecular genetics of bladder cancer: Emerging mechanisms of tumor initiation and progression

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2014.06.013

A 20-gene model for molecular nodal staging of bladder cancer: development and prospective assessment

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2014.06.013

A strategy for predicting the chemosensitivity of human cancers and its application to drug discovery

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2014.06.013

Trimodality therapy for bladder conservation in treatment of invasive bladder cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2014.06.013

Long-term outcomes of selective bladder preservation by combined-modality therapy for invasive bladder cancer: the MGH experience

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2014.06.013

Organ conservation in invasive bladder cancer by transurethral resection, chemotherapy and radiation: results of a urodynamic and quality of life study on long-term survivors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2014.06.013

Late pelvic toxicity after bladder-sparing therapy in patients with invasive bladder cancer: RTOG 89-03, 95-06, 97-06, 99-06.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2014.06.013

ICUD-EAU International Consultation on Bladder Cancer 2012: Radical cystectomy and bladder preservation for muscle-invasive urothelial carcinoma of the bladder

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2014.06.013

Bladder preservation therapy for muscle-invading bladder cancers on Radiation Therapy Oncology Group trials 8802, 8903, 9506, and 9706: vascular endothelial growth factor B overexpression predicts for increased distant metastasis and shorter surviva

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2014.06.013

MRE11 expression is predictive of cause-specific survival following radical radiotherapy for muscle-invasive bladder cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2014.06.013

Excision repair cross-complementing group 1 may predict the efficacy of chemoradiation therapy for muscle-invasive bladder cancer.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2014.06.013

Expression of the epidermal growth factor receptor and Her-2 are predictors of favorable outcome and reduced complete response rates, respectively, in patients with muscle-invading bladder cancers treated by concurrent radiation and cisplatin-based

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2014.06.013

APE1 and XRCC1 protein expression levels predict cancer-specific survival following radical radiotherapy in bladder cancer.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2014.06.013

Expression of TIP60 (tat-interactive protein) and MRE11 (meiotic recombination 11 homolog) predict treatment-specific outcome of localised invasive bladder cancer.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2014.06.013

BCG-mediated bladder cancer immunotherapy: identifying determinants of treatment response using a calibrated mathematical model

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2014.06.013

Preexisting BCG-specific T cells improve intravesical immunotherapy for bladder cancer.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2014.06.013

Critical analysis of contemporary clinical research in muscle-invasive and metastatic urothelial cancer: a report from the Bladder Cancer Advocacy Network Clinical Trials Working Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2014.06.013

Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2014.06.013

Superficial bladder cancer: progression and recurrence

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2014.06.013

EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder, the 2011 update

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2014.06.013

Muscle invasive bladder cancer: examining survivor burden and unmet needs

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2014.06.013

Incidence of downstaging and complete remission after neoadjuvant chemotherapy for high-risk upper tract transitional cell carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2014.06.013

Primary site and incidence of lymph node metastases in urothelial carcinoma of upper urinary tract

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2014.06.013

Assessment of the minimum number of lymph nodes needed to detect lymph node invasion at radical nephroureterectomy in patients with upper tract urothelial cancer.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2014.06.013

The extent of lymphadenectomy seems to be associated with better survival in patients with nonmetastatic upper-tract urothelial carcinoma: how many lymph nodes should be removed?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2014.06.013

Prospective randomized phase II trial of a single early intravesical instillation of pirarubicin (THP) in the prevention of bladder recurrence after nephroureterectomy for upper urinary tract urothelial carcinoma: the THP Monotherapy Study Group Tri

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2014.06.013

Prevention of bladder tumours after nephroureterectomy for primary upper urinary tract urothelial carcinoma: a prospective, multicentre, randomised clinical trial of a single postoperative intravesical dose of mitomycin C (the ODMIT-C Trial)

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2014.06.013

Robust prognostic gene expression signatures in bladder cancer and lung adenocarcinoma depend on cell cycle related genes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2014.06.013

Examining the management of muscle-invasive bladder cancer by medical oncologists in the United States.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2014.06.013

Orthotopic bladder substitution in women: functional evaluation

7 January 2021

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/25065704

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

General adherence to guideline recommendations on initial diagnosis of bladder cancer in the United States and influencing factors

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/25065704

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Characterization of a human, sex steroid-responsive transitional cell carcinoma maintained as a tumor line (R198) in athymic nude mice.

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/25065704

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1016/J.UROLONC.2014.06.013

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6776416&resulttype=core&format=json

12 May 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6776416&resulttype=core&format=json

12 May 2020

PubMed publication ID

25065704

1 reference